Therapy Areas: Allergy
Blacksmith Medicines granted US patent for antibacterial compounds targeting LpxC
2 July 2025 - Blacksmith Medicines Inc, a California-based biopharma company involved in discovering and developing therapeutics targeting metalloenzymes, announced on Tuesday that the United States P...
Alvotech reports positive topline results for Xolair biosimilar study
25 June 2025 - European biotech company Alvotech S.A. (NASDAQ:ALVO), US-based biopharmaceutical company Kashiv Biosciences LLC and Advanz Pharma, a UK-based pharmaceutical company with a focus on spec...
DBV Technologies secures up to USD306.9m to advance Viaskin peanut patch programme
28 March 2025 - Clinical-stage biopharmaceutical company DBV Technologies (Euronext Paris:DBV) (Nasdaq Capital Market:DBVT) on Friday announced a financing agreement of up to USD306.9m (EUR284.5m), in...
Celltrion's OMLYCLO receives US FDA approval
10 March 2025 - South Korea-based biopharmaceutical company Celltrion announced on Sunday that it has received approval from the US Food and Drug Administration (FDA) for the company's OMLYCLO (o...
Kenox Pharmaceuticals partners with Lactiga US
10 March 2025 - United States-based company that specialises in pharmaceutical aerosol product development Kenox Pharmaceuticals Inc. announced on Monday that is partnering with Lactiga US, Inc, a bio...
Health Canada approves ALK's ACARIZAX for young children with dust mite allergy
7 March 2025 - Danish pharmaceutical company ALK-Abelló A/S (ALK) (CPH:ALK-B) said on Friday that it has received approval from Health Canada for its ACARIZAX tablet to treat children aged five...